Bafilomycin C₁

V-ATPase inhibitor



ALX-380-209-M001	1 mg	514.00 USD

Macrolide antibiotic that acts as a specific inhibitor of vacuolar-type H⁺-ATPase. Shows antibacterial, antifungal, insecticidal and antihelmintic activity. Potential antiosteoporotic agent in treating bone lytic diseases.

Product Specification

Alternative Name:	L-681,110A1

Formula:	C₃₉H₆₀O₁₂

MW:	720.4

Purity:	≥95% (HPLC)

Appearance:	White to light-brown solid.

CAS:	88979-61-7

Source/Host:	Isolated from Streptomyces sp. MST-AS5338.

Solubility:	Soluble in 100% ethanol, methanol, dimethyl formamide oder DMSO.

Long Term Storage:	-20°C

Use/Stability:	May undergo transformation to methyl ketal on long term storage in methanol. We recommend to use fresh solutions.

Hazard:	TOXIC.

Handling:	Protect from light.

Please mouse over

Product Literature References

Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis: J. Xu, et al.; Histol. Histopathol. 222, 443 (2007), Abstract;

Bafilolides, potent inhibitors of the motility and development of the free-living stages of parasitic nematodes: E. Lacey, et al.; Int. J. Parasitol. 25, 349 (1995), Abstract;

Purification of vacuolar ATPase with bafilomycin C1 affinity chromatography: T.J. Rautiala, et al.; BBRC 194, 50 (1993), Abstract;

Metabolic products of microorganisms. 224. Bafilomycins, a new group of macrolide antibiotics. Production, isolation, chemical structure and biological activity: G. Werner, et al.; J. Antibiot. (Tokyo) 37, 110 (1984), Abstract;